Compare iShares MSCI South Korea ETF (EWY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Twist Bioscience Corp — how do they compare? iShares MSCI South Korea ETF trades at $178.26 (market cap $26.25B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: iShares MSCI South Korea ETF is far larger — about 2.6× Twist Bioscience Corp's market cap, and iShares MSCI South Korea ETF is more actively traded (19,056,075 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and Twist Bioscience Corp for 27 Days on average.
| EWY | TWST | |
|---|---|---|
Market Cap | $26.25B | $10.08B |
Volume | 19,056,075 | 4,229,037 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $205.00 |
52-Week Low | $80.72 | $25.45 |
Typical Hold Time | 46 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $183.72, down 1.44% amid mixed technical signals and KOSPI volatility driven by semiconductor sector sensitivity. The ETF shows neutral momentum with bullish moving averages but faces resistance near $185. Recent news highlights South Korea's strong 2026 market performance and AI-driven semiconductor demand, though concerns persist about high oil prices and rising US yields impacting tech valuations.
Outlook remains cautiously optimistic given EWY's heavy concentration in Samsung and SK hynix, which benefit from AI memory cycle strength. Key risks include reliance on two stocks, geopolitical tensions, and macroeconomic pressures. The ETF offers exposure to South Korea's tech-led growth but requires monitoring of memory cycle trends and foreign investor flows.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
